PD-L1 expression
|
Vulvar Cancer
|
PD-L1 expression
|
Vulvar Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Vulvar Cancer
|
NTRK3 fusion
|
Vulvar Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Vulvar Cancer
|
NTRK2 fusion
|
Vulvar Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Vulvar Cancer
|
NTRK1 fusion
|
Vulvar Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Vulvar Cancer
|
NTRK3 fusion
|
Vulvar Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Vulvar Cancer
|
NTRK2 fusion
|
Vulvar Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Vulvar Cancer
|
NTRK1 fusion
|
Vulvar Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Vulvar Cancer
|
MSI-H/dMMR
|
Vulvar Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Vulvar Cancer
|
TMB-H
|
Vulvar Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
GC Sensitive: A2 - Guideline
|
GC Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
erlotinib Sensitive: A2 - Guideline
|
erlotinib Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
cisplatin + vinorelbine Sensitive: A2 - Guideline
|
cisplatin + vinorelbine Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
CP Sensitive: A2 - Guideline
|
CP Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
Vulvar Cancer
|
No biomarker
|
Vulvar Cancer
|
5-fluorouracil + mitomycin Sensitive: A2 - Guideline
|
5-fluorouracil + mitomycin Sensitive: A2 - Guideline
|
PD-L1 negative
|
Vulvar Cancer
|
PD-L1 negative
|
Vulvar Cancer
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Vulvar Cancer
|
PD-L1 overexpression
|
Vulvar Cancer
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|